^
Association details:
| Biomarker: | EGFR G719A + EGFR T790M |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Exceptional response to afatinib in a patient with persistent G719A EGFR-mutant NSCLC
Published date:
04/21/2022
Excerpt:
We present a patient with metastatic NSCLC harboring a compound EGFR mutation with co-occurring G719A and T790M mutation….Subsequent administration of afatinib led to a clinical and radiological response.
DOI:
https://doi.org/10.2217/lmt-2021-0001
Test:
